Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Treatment for Generalized Anxiety Disorder (GAD)
NCT00620776Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Oct 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of venlafaxine in generalized anxiety disorder (GAD) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Hamilton Anxiety Rating Scale at 24 weeks. Started Oct 2006; status: completed.
02
Drugs
venlafaxine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00620776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00620776.